Dainippon Sumitomo's Amlodin’s Switch To New Tablet Smooth
This article was originally published in PharmAsia News
Executive Summary
At a press conference in Osaka, Dainippon Sumitomo Pharma President Kenjiro Miyatake said calcium antagonist Amlodin's switch to orally disintegrating tablets will be 60 percent complete in 2008. As the patent for Amlodin expires in July, DSP will launch generic hypertension drug irbesartan next fiscal quarter. Irbesartan has been prescribed concomitantly with Amlodin to offset competition from generic drugs. DSP will launch schizophrenia drug Lonasen in April and jointly promote it with Osaka-based Yoshitomi Yakushi. DSP has been investing in London-based Bio venture fund Apposite and will invest in more seed projects via the fund. (Click for more - Japanese language